Literature DB >> 5413950

Effect of ergotamine and ergometrine on forearm venous compliance in man.

O G Brooke, B F Robinson.   

Abstract

The effect of ergotamine and ergometrine on the venous compliance of the forearm has been studied in normal persons. Ergotamine tartrate (0.25 mg. intravenously) led to a fall in venous compliance amounting to 49% on average, while ergometrine maleate (0.25 mg. intravenously) caused a reduction of 41%; these changes were statistically significant. The potent veno-constrictor action of these ergot alkaloids appears to be a major component of the circulatory response to small doses and may be important in provoking the harmfull cardiovascular side-effects (such as angina and pulmonary oedema) that are sometimes observed in patients with pre-existing heart disease.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5413950      PMCID: PMC1699081          DOI: 10.1136/bmj.1.5689.139

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  Ergotamine tartrate: its history, action, and proper use in the treatment of migraine.

Authors:  A P FRIEDMAN; T J VON STORCH; S ARAKI
Journal:  N Y State J Med       Date:  1959-06-15

2.  On some physiological actions of ergot.

Authors:  H H Dale
Journal:  J Physiol       Date:  1906-05-31       Impact factor: 5.182

3.  Observations on the action of the hydrogenated alkaloids of the ergotoxine group on the circulation in man.

Authors:  H BARCROFT; H KONZETT; H J C SWAN
Journal:  J Physiol       Date:  1951-02       Impact factor: 5.182

4.  Reversal of the depressor action of N-isopropylarterenol (isuprel) by ergotamine and ergotoxine.

Authors:  A M LANDS; F P LUDUENA; J I GRANT; E ANANENKO; M L TAINTER
Journal:  J Pharmacol Exp Ther       Date:  1950-11       Impact factor: 4.030

5.  The hemodynamic effects of hypotensive drugs in man; dihydroergocornine.

Authors:  E D FREIS; J R STANTON
Journal:  J Clin Invest       Date:  1949-11       Impact factor: 14.808

6.  Effect on forearm arteries and veins of attenuation of the cardiac response to leg exercise.

Authors:  B F Robinson; A G Wilson
Journal:  Clin Sci       Date:  1968-08       Impact factor: 6.124

  6 in total
  7 in total

1.  Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Ergotamine-induced solitary rectal ulcer.

Authors:  O Shpilberg; M Ehrenfeld; D Abramowich; Y Samra; L Bat
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

3.  Ergonovine-induced constrictions of epicardial coronary arteries in conscious dogs: alpha-adrenoceptors are not involved.

Authors:  J Holtz; W Held; O Sommer; G Kühne; E Bassenge
Journal:  Basic Res Cardiol       Date:  1982 May-Jun       Impact factor: 17.165

4.  Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Ergotamine abuse and extra-hepatic portal hypertension.

Authors:  P E Fisher; D B Silk; N Menzies-Gow; M Dingle
Journal:  Postgrad Med J       Date:  1985-05       Impact factor: 2.401

7.  Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.

Authors:  W H Aellig; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.